Edition:
United Kingdom

People: Beigene Ltd (BGNE.OQ)

BGNE.OQ on NASDAQ Stock Exchange Global Select Market

116.53USD
9:00pm BST
Change (% chg)

$2.54 (+2.23%)
Prev Close
$113.99
Open
$115.00
Day's High
$118.34
Day's Low
$113.07
Volume
185,450
Avg. Vol
102,403
52-wk High
$194.56
52-wk Low
$105.19

Liang, Howard 

Mr. Howard Liang, Ph.D. is Chief Financial Officer and Chief Strategy Officer of the company since July 2015. Prior to joining us, from 2005 to 2015, Dr. Liang was at Leerink Partners LLC, a leading investment bank specializing in the healthcare industry, where he served as a Managing Director and Head of Biotechnology Equity Research. Dr. Liang served as a Senior Biotechnology Analyst at two full-service investment banks: A.G. Edwards Inc., from 2004 to 2005, and JMP Securities, from 2003 to 2004. From 2000 to 2003, Dr. Liang served as an Associate Analyst at Prudential Securities, where he covered major and specialty pharmaceuticals. Before Wall Street, from 1992 to 2000, Dr. Liang was with Abbott Laboratories, where he was a Senior Scientist and a member of one of the pharmaceutical industry’s leading structure-based discovery teams. During his career as a scientist, Dr. Liang authored a review and 13 papers including six in Nature, Science, and Proceedings of the National Academy of Sciences. Dr. Liang received his B.S. in Chemistry from Peking University in July, 1985, and both his MBA and Ph.D. in Biochemistry and Molecular Biology from the University of Chicago in June, 2001 and March, 1992 respectively.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --